Satellos Bioscience (TSX:MSCL) Interest Expense : C$0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Satellos Bioscience Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Satellos Bioscience's interest expense for the three months ended in Dec. 2024 was C$ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was C$0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Satellos Bioscience's Operating Income for the three months ended in Dec. 2024 was C$ -7.81 Mil. Satellos Bioscience's Interest Expense for the three months ended in Dec. 2024 was C$ 0.00 Mil. Satellos Bioscience has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Satellos Bioscience Interest Expense Historical Data

The historical data trend for Satellos Bioscience's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Satellos Bioscience Interest Expense Chart

Satellos Bioscience Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

-0.02

-0.99

-0.18

Satellos Bioscience Quarterly Data
	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial													-	-	-	-	-

Satellos Bioscience Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

Satellos Bioscience (TSX:MSCL) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Satellos Bioscience's Interest Expense for the three months ended in Dec. 2024 was C$0.00 Mil. Its Operating Income for the three months ended in Dec. 2024 was C$-7.81 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was C$0.00 Mil.

Satellos Bioscience's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Satellos Bioscience had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Satellos Bioscience Inc has no debt.

Satellos Bioscience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (TSX:MSCL) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

MSCLF:USA 0ITA:Germany

Address

200 Bay Street, Suite 2800, Royal Bank Plaza, South Tower, Toronto, ON, CAN, M5J 2J1

Website

https://www.satellos.com

Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

Satellos Bioscience Headlines

No Headlines